PharmaShots | Incisive News in 3 Shots

Subscribe Now

cancer immunotherapies

Gilead and Jounce's JTX-1811 Receives US FDA's IND Clearance for Cancer Immunotherapies

Gilead and Jounce's JTX-1811 Receives US FDA's IND Clearance for Cancer Immunotherapies

June 16, 2021

Gilead Signs an Exclusive License Agreement with Jounce for Cancer Immunotherapies

Gilead Signs an Exclusive License Agreement with Jounce for Cancer Immunotherapies

September 2, 2020

Gilead and Kite Sign a Three Years Agreement with oNKo-innate to Discover Cancer Immunotherapies

Gilead and Kite Sign a Three Years Agreement with oNKo-innate to Discover Cancer Immunotherapies

April 22, 2020

Janssen Signs a Worldwide Collaboration with Fate Therapeutics for Novel iPSC-Derived Cell-Based Cancer Immunotherapies

Janssen Signs a Worldwide Collaboration with Fate Therapeutics for Novel iPSC-Derived Cell-Based Cancer Immunotherapies

April 6, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us